Mostrar registro simples

dc.contributor.authorMartínez Gil, Luis
dc.contributor.authorAyllón Barasoain, Juan 
dc.contributor.authorOrtigoza, Mila Brum
dc.contributor.authorGarcía Sastre, Adolfo
dc.contributor.authorShaw, Megan L.
dc.contributor.authorPalese, Peter
dc.date.accessioned2023-11-13T08:06:51Z
dc.date.available2023-11-13T08:06:51Z
dc.date.issued2012
dc.identifier.urihttp://hdl.handle.net/10259/7998
dc.description.abstractThe continuous emergence of virus that are resistant to current anti-viral drugs, combined with the introduction of new viral pathogens for which no therapeutics are available, creates an urgent need for the development of novel broad spectrum antivirals. Type I interferon (IFN) can, by modulating the cellular expression profile, stimulate a non-specific antiviral state. The antiviral and adjuvant properties of IFN have been extensively demonstrated; however, its clinical application has been so far limited. We have developed a human cell-based assay that monitors IFN-β production for use in a high throughput screen. Using this assay we screened 94,398 small molecules and identified 18 compounds with IFN-inducing properties. Among these, 3 small molecules (C3, E51 and L56) showed activity not only in human but also in murine and canine derived cells. We further characterized C3 and showed that this molecule is capable of stimulating an anti-viral state in human-derived lung epithelial cells. Furthermore, the IFN-induction by C3 is not diminished by the presence of influenza A virus NS1 protein or hepatitis C virus NS3/4A protease, which make this molecule an interesting candidate for the development of a new type of broad-spectrum antiviral. In addition, the IFN-inducing properties of C3 also suggest its potential use as vaccine adjuvant.en
dc.description.sponsorshipThis work was supported in part by National Institutes of Health grants: HHSN272200900032C and U54308 AI057159. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherPublic Library of Sciencees
dc.relation.ispartofPLoS ONE. 2012, V. 7, n. 11, e49049es
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.subject.otherSaludes
dc.subject.otherHealthen
dc.subject.otherMicrobiologíaes
dc.subject.otherMicrobiologyen
dc.subject.otherEnfermedades infecciosases
dc.subject.otherCommunicable diseasesen
dc.titleIdentification of Small Molecules with Type I Interferon Inducing Properties by High-Throughput Screeningen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0049049es
dc.identifier.doi10.1371/journal.pone.0049049
dc.identifier.essn1932-6203
dc.journal.titlePLoS ONEes
dc.volume.number7es
dc.issue.number11es
dc.page.initiale49049es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Arquivos deste item

Thumbnail

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples